EL-22
Pre-clinical- Indications
- Obesity, Muscle loss
Company intelligence / Profile preview
PMGC Holdings Inc.
Newport Beach, California, United Statespmgcholdings.com ↗
- Ownership
- Public · ELAB
- Employees
- ~3
- Development stage
- Preclinical
01
Overview
Developing EL-22, a lead asset leveraging an engineered probiotic approach to address obesity's issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists
- Therapeutic areas
- Metabolic DisordersEndocrinology
- Modalities
- Engineered probiotics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Canadian Universities
04
Financials
- Market cap
- $1.3M
- Total revenue
- $590.1K
- Enterprise value
- $-3.5M
Beyond the preview
Go deeper on PMGC Holdings Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMGC Holdings Inc..